New Retina Radio
02.23.23
The FDA approval of pegcetacoplan (Syfovre, Apellis Pharmaceuticals) is a historic moment for the field of retina, finally providing a treatment option for patients with geographic atrophy. Allen C. Ho, MD, and Robert L. Avery, MD, share their initial reactions to the approval and discuss the potential effect on patient care and clinical practice.
View full description +
Subscribe
11.13.25
AAO '25: GLP-1s and AMD, and Parity in Retina CareAleksandra Rachitskaya, MD; and Julia Haller, MD
Editorially independent content, supported by Genentech.
11.10.25
Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLERahul Khurana, MD; and Arshad Khanani, MD, MA
Editorially independent content, supported by Genentech.
11.06.25
AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt DiseasePeter Kaiser, MD; and Michel Michaelides, MD
Editorially independent content, supported by Genentech.
11.03.25
The Nuts and Bolts of GA Therapy: The Discussions ContinueCharles Wykoff, MD, PhD; Hasenin Al-khersan, MD; and Nakul Singh, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
10.23.25
Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDRAllen Ho, MD; and Charles Wykoff, MD, PhD
Editorially independent content, supported by Genentech.
10.10.25
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient CareNiki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD
Editorially Independent Content Supported by Genentech
10.09.25
The Nuts and Bolts of GA Therapy: The Opening SessionsCharles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
10.02.25
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring VisionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
Show More